Roche Analyst Event Monday, 5 December 2016 This Presentation Contains Certain Forward-Looking Statements

58th ASH Annual Meeting, San Diego

Roche Analyst Event Monday, 5 December 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Introduction

Karl Mahler Head Investor Relations Agenda

Welcome Karl Mahler, Head of Investor Relations

New paths in hematology Nancy Valente, M.D., Vice President, Product Development Hematology/Oncology

Gazyva - New standard of care in FL (iNHL) David Traub, M.D., Lifecycle Leader anti-CD20 Franchise

Venclexta – New data in CLL, NHL, AML and MM Reema Mewar, Ph.D., Lifecycle Leader Venclexta/Venclyxto

Polatuzumab vedotin – A potent ADC in NHL Michael Wenger, M.D., Senior Group Medical Director

Q&A

5 2016 onwards: Significant launch activities

Venclexta R/R CLL with 17p del Cotellic + Zelboraf

BRAFmut melanoma Alecensa

2L ALK+ NSCLC NMEs Tecentriq OCREVUS 2L+ bladder cancer RMS/ PPMS Tecentriq Emicizumab (ACE910) Lampalizumab 2L+ all-comers NSCLC Hemophilia A Geographic atrophy 2016 2017 2018

Gazyva Perjeta + Herceptin Tecentriq+Avastin+chemo

Refractory iNHL (GADOLIN) eBC HER2+ (APHINITY) 1L NSCLC

Gazyva Tecentriq + Avastin

1L iNHL (GALLIUM) 1L RCC line line Actemra Alecensa

extensions Giant cell arteritis (GiACTA) 1L ALK+ NSCLC

Oncology/ FDA Breakthrough Neuroscience Ophthalmology Immunology hematology Therapy Designation

Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed. 6 Roche significantly advancing patient care Five BTD designations in hematology

Year Molecule Actemra (Giant cell arteritis) Breakthrough Therapy Alecensa (1L ALK+ NSCLC) 14 Designations 2016 Ocrevus (PPMS) Venclexta (AML) Venclexta + Rituxan (R/R CLL) Rank Company # Actemra (Systemic sclerosis) 1 Roche 14 Tecentriq (NSCLC) 2015 2 Novartis 11 Venclexta (R/R CLL 17p del) 3 BMS 10 Emicizumab/ACE 910 (Hemophilia A) 4 Merck 9 Esbriet (IPF) 2014 Lucentis (Diabetic retinopathy) 5 AbbVie 7 Tecentriq (Bladder) 6 Pfizer 7 Alecensa (2L ALK+ NSCLC) 2013 Gazyva (1L CLL)

Source: http://www.focr.org/breakthrough-therapies as at Oct 2016; PPMS=Primary Progressive Multiple Sclerosis; CLL=Chronic 7 Lymphocytic Leukemia; AML=acute myeloid leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Fibrosis

ASH 2016: Improving upon on standard of care Key presentations

DLBCL FL CLL

Polatuzumab shows Establishing Gazyva as SOC Venclexta unfolding promiseDLBCL (Ph2 ROMULUS in (Ph3 GALLIUMFL in 1L and Ph3 (run-in dataCLL for Ph3 CLL14) R/R and Ph1/2 in 1L) GADOLIN in Rituxan- ref FL) Rituxan-CHOP remains MabThera SC comparable to standard of care IV (Ph3 SABRINA)

AML MM Hemophilia

Venclexta + LDAC with strong Strong efficacy of Venclexta Real world data of patients efficacyAML/MDS in 1L unfit AML (Ph2) in R/R MMMM (Ph1 monotherapy withHemophilia hemophilia A to support and combination data) further development of emicizumab

8 New paths in hematology

Nancy Valente, M.D. Vice President, Product Development Hematology/Oncology Unmet need in hematology

Hematology portfolio & strategy

Cancer immunotherapy

Emicizumab update

10 Today: Hematology indications still represent large unmet need

DLBCL FL CLL

40% of DLBCL Still no cure, many patients Still no cure, many patientsDLBCL relapse and experience multipleFL patients achieveCLL succumb to their relapses before succumbing incomplete responses and disease to their disease require chronic treatment

AML/MDS MM Hemophilia

SOC in AML has made little Foundation of therapy based High unmet need for patients progressAML/MDS in decades, on two drugMM classes associated withHemophilia inhibitors to Factor VIII; combinations will significantly with significant side effects; Existing therapies are hampered improve outcomes for patients targeted therapy combinations by burden on therapy and to advance SOC compliance Blood cancer: Still high unmet medical need Incidence cases reach 330,000 pts1

aCD20/CD3 TCB 1 aCD20/CD3 TCB 2

polatuzumab vedotin

idasanutlin LSD1 inhibitor

BET inhibitor

ChK1 inhibitor

= Roche marketed = Roche in development undisclosed ADC

¹ Datamonitor; incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); NHL=non-hodgkin`s lymphoma; DLBCL (aNHL)=diffuse large B-cell lymphoma; FL (iNHL)=follicular lymphoma; ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; CLL=chronic lymphoid leukemia; MM= multiple myeloma; MDS=myelodysplastic syndrome; Venclexta in collaboration with AbbVie; Cotellic in collaboration with Exelixis; Gazyva in collaboration with Biogen; polatuzumab vedotin in collaboration with Seattle Genetics; LSD1inhibitor in collaboration with Oryzon Genomics; ChK1i in collaboration with Array BioPharma 12 Unmet need in hematology

Hematology portfolio & strategy

Cancer immunotherapy

Emicizumab update

13 Gazyva initial trial program completed New standard of care in iNHL and CLL Primary end-point: CLL11: Ph III 1L Chronic Lymphocytic Leukemia (CLL) Gazyva + chlorambucil 1L CLL PFS Rituxan + chlorambucil n=781 Approved in Q4 2013  chlorambucil

GADOLIN: Ph III Rituxan-refractory Follicular Lymphoma (FL)

Induction Maintenance PFS CR, PR, Rituxan-refractory FL Gazyva + bendamustine Gazyva SD Approved in Q1 2016  (indolent NHL) q2mo x 2 years n=411 bendamustine

GALLIUM: Ph III 1L Follicular Lymphoma (FL) Induction Maintenance Gazyva + CHOP or Gazyva Gazyva + CVP or q2mo x 2 years PFS  1L FL Gazyva + bendamustine (indolent NHL) CR, PR Stopped at interim analysis n=1401 Rituxan + CHOP or Rituxan Rituxan + CVP or q2mo x 2 years Rituxan + bendamustine

GOYA: Ph III 1L Diffuse Large B-cell Lymphoma (DLBCL)

Gazyva + CHOP Front-line DLBCL PFS (aggressive NHL) Endpoint not met  n=1418 Rituxan + CHOP

Gazyva in collaboration with Biogen; CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, 14 Vincristine and Prednisolone Establishing Gazyva as new CD20 backbone Improving the standard of care in iNHL and CLL

Rituxan sales split by indication

1L CLL Gazyva in 1L CLL 5% 1L CLL Fit (CLL 11) 6%

R/R CLL 6% Gazyva in 1L FL (iNHL) (GALLIUM) iNHL 49% Gazyva in Rituxan-refractory 1L aNHL FL (iNHL) (GADOLIN) 27%

R/R aNHL 6%

CLL=chronic lymphocytic leukemia; iNHL=indolent non-hodgkin’s lymphoma; FL=follicular lymphoma; aNHL=aggressive NHL; DLBCL=diffuse large B cell lymphoma; Gazyva in collaboration with Biogen 15 Evolving landscape in NHL Increasing segmentation and new surrogate endpoints

Present Future

2014 2014 2024 Competition No competition for 17 years Increased competition

Combination therapies for diagnostic subsegments Segmentation All comers studies ABC Unclassified GCB DLBCL (aNHL)

Traditional Potential Traditional Endpoints Surrogate Endpoints New PFS OS MRD CR30 PFS OS Endpoints CLL NHL 5 yrs 7 yrs 15mo 30mo 5 yrs 7 yrs

Induction Induction Early Filing

ABC=activated B-cell, GCB=germinal center B-cell 16 Increasing segmentation in 1L DLBCL (aNHL) New combinations based on Rituxan backbone

Elevated BCL-2 % of Median OS Segment incidence [months]

~50% All Comers 100% >60 Double Positive Double Hit BCL-2 and myc* BCL-2 and myc GCB 55% >60

ABC** 30% 30-40

18-33% Double Positive 24 ~50% (46% of ABC) Double-Hit 5-10% 12 Un- ABC classified GCB ** worse outcomes in ABC may be driven by higher proportion of double positive patients ~30% ~15% ~55% Rituxan backbone

Lenalidomide (ROBUST)

Ibrutinib (PHOENIX)

*46% of ABC patients are double positive (Hu S et l. Blood, 2013); Source: Roche internal data presented during REFORCE F2F Feb- 2015; Johnson N et al, JCO 2012; Hu S et al, Blood 2013; Iqbal J et al. Clin Can Res 2011; Iqbal J et al. JCO, 2006; Davis et al. Nature 2010; Haberman T et al, JCO 2006; Thieblemont C et al. JCO 2011 17 ABC=activated B-cell, GCB=germinal center B-cell Surrogate endpoints to accelerate development MRD level Predict long-term outcome early on <10-4 ≥10-4 to <10-2 ≥10-2

Novel endpoints:

• MRD in CLL

• CR30 months in FL

• PET-CT negative CR in

DLBCL

MRD=minimal residual disease; PET-CT=positron emission tomography-computed tomography 18 Frequency of leukemic cells leukemic of Frequency

Induction Maintenance

Time Developing new combinations in NHL Building on the CD20 backbone and new agents

Rituxan + Chemo

Eliminate or replace targeted agent Rituxan or Gazyva + with Polatuzumab + Venclexta

Anti CD20/CD3 Polatuzumab Venclexta TCB + NME ADC + Tecentriq

TCB=T cell bispecific; NME=new molecular entity; ADC=antibody drug conjugate 19 Innovative trial designs in NHL needed Prioritization and early decision making important

Approved Approved Progression Backbone Combination Studies Backbone Combination Studies in 2016-2018

Venclexta Venclexta Polatuzumab Polatuzumab Standard of care Tecentriq R/G + Chemo Ph3 in 1L FL/DLBCL R/G + Chemo Tecentriq Lenalidomide Lenalidomide

Ibrutinib Ibrutinib

Venclexta Chemo–targeted Venclexta G + Pola Tecentriq Accelerated approval in R/R Tecentriq Ph3 in 1L FL/DLBCL G + Pola Lenalidomide Lenalidomide

Polatuzumab Polatuzumab

Tecentriq Improved Tolerability Improved Tecentriq Idasanutlin Chemo-free Idasanutlin R/G Tecentriq + Lenalidomide Accelerated approval in R/R R/G Tecentriq + Lenalidomide Ph3 in 1L FL/DLBCL Ibrutinib Ibrutinib Venclexta Venclexta Lenalidomide Lenalidomide

Venclexta in collaboration with AbbVie; Polatuzumab vedotin in collaboration with Seattle Genetics 20

Approved Backbone Combination Studies

Venclexta

Polatuzumab R/G + Chemo Tecentriq Lenalidomide

Ibrutinib

Venclexta G + Pola Tecentriq Lenalidomide

Polatuzumab

Tecentriq

Idasanutlin R/G Tecentriq + Lenalidomide Ibrutinib

Venclexta

Lenalidomide Overview hematology pipeline Phase I Phase II Phase III Approved

14 molecules in the clinic including 9 NMEs Rituxan / Rituxan SC NHL, CLL Gazyva NHL, CLL CLL* x 3 Venclexta* NHL, AML, MM

Polatuzumab vedotin NHL

Tecentriq NHL, MDS, MM

Cotellic AML

undisclosed ADC NHL

Idasanutlin AML, NHL

aCD20/CD3 TCB 1 Hematological tumors

aCD20/CD3 TCB 2 Hematological tumors

LSD1i AML

ChK1i Lymphoma

BETi AML

Emicizumab Hemophilia A

* Venclexta in collaboration with AbbVie; Polatuzumab vedotin in collaboration with Seattle Genetics; LSD1i in collaboration with Oryzon Genomics; Cotellic in collaboration with Exelixis; ChK1i in collaboration with Array BioPharma; NHL=non-hodgkin`s lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrom; AML=acute myeloid 21 leukemia Unmet need in hematology

Hematology portfolio & strategy

Cancer immunotherapy

Emicizumab update

22 Why is immunotherapy important in hematology?

Broad portfolio & History in hematology strong scientific rationale

• Rituxan was technically the first cancer

immunotherapy

• Gazyva was the first glyoengineered

antibody to enhance ADCC and ADCP -

IDOi

TCB 1 TCB 2 TCB

aTIGIT

aOX40 aCSF

• Tecentriq showed tumor shrinkage in Tecentriq

aCD20/CD3 aCD20/CD3 aCD20/CD3 Phase I hematologic malignancies AML • Checkpoint inhibitors have shown

promising efficacy in Hodgkin’s disease, MDS NHL and MM

DLBCL

ADCC=antibody-dependent cellular cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; NHL=non-hodgkin`s lymphoma; MM=multiple myeloma; AML=acute myeloid leukemia; MDS=myelodysplastic syndrom; FL=follicular lymphoma; DLBCL=diffuse MM large B cell lymphoma; TCB=T cell bispecific 23

Clinical, pre-clinical or MOA suggestive of activity No data Lack of activity or antagonism expected Solid tumors CIT development program by tumor type Solid tumors Lung (NSCLC & SCLC) Breast (TNBC & HER2+) Tecentriq Ph1 Tecentriq (2L/3L)  Tecentriq +chemo (TNBC) Ph3 Tecentriq chemo Avastin Ph1 +Kadcyla or Herceptin+ Tecentriq (1L Dx+) Ph3 Tecentriq Ph1 Perjeta (HER2+) Tecentriq +Cotellic Ph1 Tecentriq +chemo (3x 1L trials) Ph3 Tecentriq +Kadcyla (HER2+ 2L) Ph2 aOX40 Tecentriq Ph1 Tecentriq +chemo Avastin (1L) Ph3 Tecentriq +T-VEC* Ph1 aCEA/CD3 TCB Tecentriq Ph1 Tecentriq (adjuvant) Ph3 Tecentriq +entinostat* Ph2 IDOi Tecentriq Ph1 Tecentriq +Tarceva or Alecensa Ph1 emactuzumab Tecentriq Ph1 RCC Tecentriq +chemo (SCLC) Ph3 aCEA-IL2v FP Tecentriq Ph1 Tecentriq +epacadostat* Ph1 Tecentriq Avastin Ph2 aFAP-IL2v FP Ph1 Tecentriq +Avastin Ph3 Bladder aCD40 Tecentriq Ph1 Sarcoma emactuzumab aCD40 Ph1 Tecentriq (2L+ UBC)  Tecentriq +NY-ESO-1 (CMB305)* Ph2 aCD40 +vanucizumab Ph1 Tecentriq +BCG (NMIBC) Ph1 Tecentriq +vanucizumab Ph1 Tecentriq (2L+ UBC) Ph3 Melanoma aTIGIT Tecentriq Ph1 Tecentriq (Dx+ adjuvant MIBC) Ph3 Tecentriq +Zelboraf Cotellic Ph1 Tecentriq +daratumumab* Ph1 Tecentriq + chemo (1L mUC) Ph3 Tecentriq +Cotellic Zelboraf Ph3 Tecentriq +IFN or ipilimumab* Ph1 Hematological tumors Tecentriq +A2Ai (CPI-444)* Ph1 Tecentriq +varlilumab* Ph1 Tecentriq ±lenalidomide ±daratumumab* (R/R MM) Ph1 Tecentriq +CXCR4 (BL8040)* Ph1 Tecentriq ±azacitidine (MDS) Ph1 Tecentriq +mRNA vaccines* Ph1 Tecentriq +Gazyva/Rituxan +tazemetostat* (R/R FL and DLBCL) Ph1 Colon Tecentriq +Gazyva/Rituxan+polatuzumab (R/R FL and DLBCL) Ph2 Tecentriq +Gazyva/Rituxan+lenalidomide (R/R FL and DLBCL) Ph1 Tecentriq +Cotellic (3L+) Ph3 Tecentriq +Gazyva/Rituxan+bendamustine/CHOP (1L FL and DLBCL) Ph1 Tecentriq +Cotellic+Avastin (2L+) Ph1 aCD20/CD3 TCB 1 Ph1 Tecentriq +T-VEC* Ph1 Tecentriq +CD19 CAR-T (KTE-C19)* (refractory aNHL) Ph1 Ovarian Tecentriq +guadecitabine* AML Ph1 Tecentriq +rucaparib* Ph1 Tecentriq +CXCR4 (BL8040)* AML Ph1

 = approved; *External collaborations; Other CIT NMEs besides Tecentriq As of Nov 5th 24 aCD20/CD3 TCBs as new backbone in NHL

Malignant CD20 Two shots on goal B cell 1

aCD20/CD3 TCB

MHC1

T cell receptor killing 3 1

CD8+ T cell CD3

1 aCD20/CD3 TCB binds to tumor cells or CD8+ T cells 2 Pulls together the malignant B cell and the T cell • aCD20/CD3 TCB binds to tumor cells via 3 Enables T cell killing via CD3 stimulation CD20 and to T cells via CD3, thereby enabling T cell mediated killing

TCB=T cell bispecific; T cell=cytotoxic T lymphocyte (CTL) 25

aCD20/CD3 TCB 1 aCD20/CD3 TCB 2 (gRED) (pRED)

CD20 binding CD20 CD3 binding binding CD20 binding CD3 binding Preclinical data for aCD20/CD3 TCBs presented PD-L1 combinations active

aCD20/CD3 TCB 1 (gRED) aCD20/CD3 TCB 2 (pRED)

aCD20/CD3 TCB 2 with increased aCD20/CD3 TCB 1 + aPD-L1 T cell activity in vitro

1 4 0

1 2 0

s i

s 1 0 0

l CD20 TCB (2:1)

l 8 0

r 6 0

o Other CD20-

m 4 0

u targeted TCBs (1:1)

2 0 %

-2 0 0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 T C B c o n c e n tr a tio n [p M ]

aCD20/CD3 TCB 2 with increased T cell activity ex vivo

6 CD20 TCB (2:1) )

(

0 4 Other CD20-

5 C

E targeted TCB (1:1)

Peiyin W et al., ASH 2016 Bacac M et al., ASH 2016

TCB=T cell bispecific 26 Unmet need in hematology

Hematology portfolio & strategy

Cancer immunotherapy

Emicizumab update

27 Emicizumab (ACE910) in hemophilia A Phase III inhibitor data expected in 2016 Median ABR reduction 2015 2016 2017 2018

Japanese studies OLE Chugai

Non-interventional

Inhibitor (≥12 yrs) Weight based QW dosing

Non-inhibitor (≥12 yrs) QW and Q2W dosing

Pediatrics Inhibitor Median follow Cohorts up (Months) Q4W dosing study C1 (0.3mg/kg) n=6 32.6 • Development program on track C2 (1mg/kg) n=6 27.0 • Two year follow-on data presented at WFH C3 (3mg/kg) n=6 21.4 confirm efficacy and safety profile Phase I Phase II Phase III Patient transfer *

** • Additional Phase III studies in non-inhibitors and paediatrics have started

Nogami K. et al, presented at WFH 2016 ; ABR=annual bleeding rate; OLE=open label extension; *1 patient discontinued administration due to mild injection site erythema; **1 patient did not participate in the extension study since prior treatment was sufficiently efficacious 28

ACE910 dose effect

Inhibitor patient Non-Inhibitor patient

77.1 80 -23％ 59.5 60 -62％ -100％ 40 36.5 -49％ -58％ 29.1 18.5 -80％ 20 15.5 7.2 0

Annualized bleeding rate bleeding Annualized 0

= On demand/Prophylaxis = 1.0mg/kg = 0.3mg/kg = 3.0mg/kg Gazyva - New standard of care in FL (iNHL)

David Traub, M.D. Lifecycle Leader anti-CD20 Franchise Introduction: Gazyva

Gazyva in NHL

Gazyva development program

MabThera/Rituxan SC

30 MoA: Gazyva (glycoengineered anti-CD20 MAb) Optimized for enhanced ADCC and ADCP

Product profile

• Gazyva is a type II anti-CD20 antibody with a glycoengineered Fc portion to enhance binding to the FcγRIII receptor on immune cells and a variable region that binds CD20 in a distinct orientation

• Compared to Rituxan, Gazyva enhances:

1. Direct cell death 2. Antibody-dependent cell- mediated cytotoxicity (ADCC) 3. Antibody-dependent cellular phagocytosis (ADCP)

MOA=mechanism of action; ADCC=antibody-dependent cellular cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; Gazyva (obinutuzumab); Rituxan (rituximab); 31 1. Mössner E. et al., Blood 2010; 2. Ferrara C. et al., Biotechnol Bioeng 2006; 3. Dalle S. et al., Mol Cancer Ther 2011 Gazyva initial trial program completed New standard of care in iNHL and CLL Primary end-point: CLL11: Ph III 1L Chronic Lymphocytic Leukemia (CLL) Gazyva + chlorambucil 1L CLL PFS Rituxan + chlorambucil n=781 Approved in Q4 2013  chlorambucil

GADOLIN: Ph III Rituxan-refractory Follicular Lymphoma (FL)

Induction Maintenance PFS CR, PR, Rituxan-refractory FL Gazyva + bendamustine Gazyva SD Approved in Q1 2016  (indolent NHL) q2mo x 2 years n=411 bendamustine

GOYA: Ph III 1L Diffuse Large B-cell Lymphoma (DLBCL)

Gazyva + CHOP Front-line DLBCL PFS (aggressive NHL) Endpoint not met  n=1418 Rituxan + CHOP

Gazyva in collaboration with Biogen; CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, 32 Vincristine and Prednisolone Introduction: Gazyva

Gazyva in NHL (GALLIUM; GADOLIN; GOYA)

Gazyva development program

MabThera/Rituxan SC

33 Gazyva in 1L FL (iNHL) 34% risk reduction of disease progression

PFS by INV

GALLIUM phase III results: • Primary endpoint met at interim analysis (median observation time of 35 months) • Investigator assessed PFS HR expected to translates to a 1.5x longer mPFS (9 years instead of 6 years) • Gazyva based immunochemotherapy and maintenance new standard of care in 1L FL

Marcus R. et al., ASH 2016; FL=follicular lymphoma; R=Rituxan; G=Gazyva; PFS=progression free survival; INV=investigator; IRC=independent review committee; HR=hazard ratio; OS=overall survival; Data cut-off: January 31, 2016 34 Gazyva in Rituxan-relapsed FL (iNHL) 42% risk reduction of death in FL patients

OS (FL patients)

GADOLIN phase III update:

• OS benefit in FL patients and all iNHL patients • PFS benefit confirmed by nearly two years of additional follow-up • Results establish Gazyva + bendamustine induction followed by Gazyva maintenance as standard of care for Rituxan-relapsed FL patients

Cheson B. et al., ASH 2016; FL=follicular lymphoma; iNHL=indolent non-hodgkin`s lymphoma; B=bendamustine; PFS=progression free survival; OS=overall survival; HR=hazard ratio; Data cut-off: April 1, 2016 35 Gazyva in 1L DLBCL (aNHL) Outcome informs future research activities

PFS by INV

GOYA Phase III results:

• G-CHOP did not improve INV-assessed PFS compared with R-CHOP • Outcomes for secondary time-to-event endpoints were consistent with that for the primary endpoint • R-CHOP remains standard of care in this setting

Vitolo U. et al., ASH 2016; DLBCL=diffuse large B cell lymphoma; aNHL=agressive non-hodgkin`s lymphoma; G=Gazyva; R=Rituxan; CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; PFS=progression free survival; INV=investigator; HR=hazard ratio; 36 OS=overall survival; Data cut-off: April 30, 2016

1.0 Rituxan + CHOP Gazyva + CHOP (n=712) (n=706) PFS by INV 0.8

Pts with event, n (%) 215 (30.2) 201 (28.5)

HR 0.92; p=0.3868 0.6 Event-free at 3 yrs (%) 66.9 69.6 HR=0.92 (0.76, 1.12) PFS by IRC p=0.3868 0.4

HR 0.89; p=0.2736 Probability Event-free at 3 yrs (%) 70.6 72.5 OS 0.2 R-CHOP (n=712) Pts with event, n (%) 126 (17.8) 126 (17.7) G-CHOP (n=706) HR 1.00; p=0.9982 0 Event-free at 3 yrs (%) 81.4 81.2 0 6 12 18 24 30 36 42 48 54 60 Time (months) No. of patients at risk R-CHOP 712 616 527 488 413 227 142 96 41 6 G-CHOP 706 622 540 502 425 240 158 102 39 2 Introduction: Gazyva

Gazyva in NHL

Gazyva development program

MabThera/Rituxan SC

37 Development program in NHL Gazyva trials in DLBCL…

Compound Combination Study name Indication PPh1 1 PPh2 2 PPh3 3 Gazyva +bendamustine GADOLIN FL (iNHL) (Rituxan refractory)  ASH Gazyva +CHOP GOYA 1L DLBCL (aNHL)  ASH Gazyva +chemo GALLIUM 1L FL ( iNHL)  ASH Venclexta* +Rituxan/+Rituxan+bendamustine CONTRALTO R/R FL (iNHL) Venclexta +Rituxan+CHOP CAVALLI 1L DLBCL (aNHL) ASH Venclexta +Rituxan+bendamustine R/R NHL Venclexta R/R CLL and R/R NHL Venclexta +Gazyva/Rituxan+polatuzumab R/R DLBCL (aNHL) and R/R FL (iNHL) polatuzumab +Rituxan/Gazyva ROMULUS R/R DLBCL (aNHL) and R/R FL (iNHL) ASH NHL polatuzumab +Gazyva/Rituxan+bendamustin R/R DLBCL (aNHL) and R/R FL (iNHL) polatuzumab +Gazyva+CHP/Rituxan+CHP 1L DLBCL (aNHL) polatuzumab +Gazyva/Rituxan+lenalidomide R/R DLBCL (aNHL) and R/R FL (iNHL) +Gazyva or Tecentriq R/R DLBCL (aNHL) and R/R FL (iNHL) +tazemetostat1** Tecentriq +Gazyva+lenalidomide R/R FL (iNHL) Tecentriq +Gazyva/Rituxan+benda or CHOP 1L FL (iNHL) and 1L DLBCL (aNHL) Tecentriq +Gazyva/Rituxan+polatuzumab R/R DLBCL (aNHL) and R/R FL (iNHL) idasanutlin +Gazyva/Rituxan R/R DLBCL (aNHL) and R/R FL (iNHL) undisclosed ADC R/R NHL

iNHL=indolent non-hodgkin`s lymphoma; aNHL=agressive NHL; DLBCL=diffuse large B cell lymphoma; FL=follicular lymphoma; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; * Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; polatuzumab vedotin in collaboration with Seattle Genetics; **External collaboration; ADC=antibody 38 drug conjugate Development program in CLL, MM, AML, MDS …and CLL

Compound Combination Study name Indication Ph1P 1 Ph2P 2 Ph3P 3 Gazyva +chemo CLL11 CLL  Gazyva +FC/bendamustin/Clb GREEN CLL and R/R CLL Venclexta +Rituxan R/R CLL and SLL Venclexta +Gazyva CLL14 CLL ASH CLL Venclexta +Rituxan MURANO R/R CLL Venclexta R/R CLL 17p  Venclexta R/R CLL after ibru/idel Venclexta +Rituxan+bendamustine R/R CLL and untreated CLL Venclexta +Gazyva R/R CLL and untreated CLL Venclexta R/R MM Venclexta +bortezomib+dexamethasone R/R MM MM monotherapy or +daratumumab** or Tecentriq R/R MM +lenalidomide or +lenalidomide+daratumumab Venclexta AML Venclexta +decitabine/+azacitidine AML Venclexta +low dose cytarabine (LDAC) 1L AML AML +Cotellic Venclexta R/R AML unfit for chemo +idasanutlin LSD1 inhibitor AML idasanutlin +cytarabine R/R AML MDS Tecentriq +azacitidine MDS aCD20/CD3 TCB1 Hematologic tumors

CLL=chronic lymphoid leukemia; R/R CLL=relapsed/refractory CLL; MM=multiple myeloma; AML=acute myeloid leukemia; MDS=myelodysplastic syndrome; FC=fludarabine, cyclophosphamide; *Venclexta in collaboration with AbbVie; Gazyva in collaboration 39 with Biogen; Cotellic in collaboration with Exelixis; **External collaboration Introduction: Gazyva

Gazyva in NHL

Gazyva development program

MabThera/Rituxan SC

40 MabThera/Rituxan SC Launches ongoing, strong uptake in most markets

• Approved in the EU in NHL and CLL • Encouraging initial uptake in the EU markets, comparable to Herceptin SC • Rituxan SC filed in the US

SC=subcutaneous; MabThera/Rituxan SC partnered with Halozyme 41 Rituxan SC in 1L FL (iNHL) Reducing healthcare burden without compromising on safety and efficacy

Progression free survival Rituxan IV Rituxan SC (n=205) (n=205) ORR (%) at EOI 84.9 84.4 CR/CRu (%) at EOI 32.2 32.2 PFS Pts with event, n (%) 57 (27.8) 50 (24.4) HR 0.84; p*=0.3696 OS Pts with event, n (%) 20 (9.8) 16 (7.8) HR 0.81; p*=0.5398

*Unstratified analysis, Wald test p value

SABRINA Phase III update:

• Comparable response rates and time-to-event data for SC versus IV administration • No new clinically relevant safety signals were identified • SC administration has positive implications for patients and healthcare professionals

Davies A.. et al., ASH 2016; FL=follicular lymphoma; SC=subcutaneous; IV=intravenous; R=Rituxan; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone; PFS=progression free survival; OS=overall survival; ORR=overall response rate; CR=complete responses; CRu=complete response unconfirmed; EOI, end-of- 42 induction; OS, overall survival; HR=hazard ratio

Induction Maintenance

8x R-CHOP IV or Rituxan IV 8x R-CVP IV q2mo x 2 years 1L FL (iNHL) CR, n=410 1.0 1x R-CHOP IV + PR 7x R-CHOP SC or Rituxan SC 1x R-CVP IV + q2mo x 2 years 0.8

7x R-CVP SC

0.6 HR=0.84 (0.57, 1.23) p=0.3696

0.4 Probability

0.2 Rituxan IV Rituxan SC 0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 Time (months) Number at risk Rituximab IV 205 196 186 176 171 162 157 156 138 73 41 35 29 14 2 0 Rituximab SC 205 188 183 169 166 164 158 154 139 81 51 48 40 23 2 0 Venclexta – New data in CLL, NHL, AML, MM

Reema Mewar, Ph.D. Lifecycle Leader Venclexta/Venclyxto Introduction: Venclexta

Venclexta in CLL

Venclexta in AML

Venclexta in NHL

Venclexta in MM

Venclexta development program

44 MoA: Venetoclax* (BCL-2 inhibitor) Restoration of apoptosis through BCL-2 inhibition

BCL-2 overexpression allows Venetoclax binds selectively to BCL-2, cancer cells to evade apoptosis by freeing pro-apoptotic proteins that initiate sequestering pro-apoptotic proteins. programmed cell death (apoptosis).

MOA=mechanism of action; * venetoclax in collaboration with AbbVie 45 Introduction: Venclexta

Venclexta in CLL (CLL14)

Venclexta in AML

Venclexta in NHL

Venclexta in MM

Venclexta development program

46 Venclexta* + Gazyva in 1L unfit CLL First efficacy data from Ph3 run-in

CLL14 study design

Run-in of phase III (CLL14): • Gazyva + Venclexta tolerable in elderly patients with CLL and clinically meaningful comorbidities • The treatment induced substantial responses with a high number of minimal residual disease (MRD) negative responses 3 months after end of therapy (at month 15) • Ph3 was fully recruited as of August 2016

Fischer K. et al., ASH 2016; *Venclexta (venetoclax) in collaboration with AbbVie; CLL=chronic lymphoid leukemia; MRD=minimal residual disease 47

Gazyva + Venclexta

Response rates (n=12) ORR 12 (100) CR 7 (58) PR 5 (42) MRD in peripheral blood (n=11) Negative 10 (91) (<10-4) Intermediate 1 (9) (≥10-4 and <10-2) Introduction: Venclexta

Venclexta in CLL

Venclexta in AML

Venclexta in NHL

Venclexta in MM

Venclexta development program

48 Venclexta* + LDAC in 1L unfit AML 61% ORR achieved Bone marrow blast count Venclexta + LDAC Response,

e 2 2 0 All patients

n i

l n (%)

e 1 2 0 (n=61) s

a 1 0 0 Phase 1 (600 mg), n=7 b

ORR 37 (61)

m Phase 2 (600 mg), n=51 o

r 5 0 CR/CRi 33 (54)

g CR 13 (21) n

a 0 h

c CRi 20 (33)

t n

e -5 0 PR 4 (7)

e p

PD 23 (38) t

s -1 0 0 e

B P a t ie n t s (n = 5 8 )

R e s p o n d e rs (C R + C R i+ P R ), n = 3 7 Phase II results: N oOveralln -r e s p o n d e survivalrs , n = 2 4 1 .0 • ORR of 61% in all patients 0 .9 0 .8

• 71% of patients achieved a ≥50% decrease 0 .7

y t

i 0 .6

l i

in BM and peripheral blast counts b

a 0 .5

b o

r 0 .4 • Combination demonstrates significant and P 0 .3 R e s p o n d e rs (C R + C R i+ P R ), n = 3 7 durable activity in patients aged ≥65y with 0 .2 N o n -r e s p o n d e rs , n = 2 4 treatment-naïve AML ineligible to receive 0 .1 1 .0 I= c e n s o r e d e v e n t 0 .0 0 .9 intensive chemotherapy 0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 0 .8 M o n th s sin c e in itia tio n o f tre a tm e n t

0 .7

y t

i 0 .6

i b

a 0 .5

Wei AH. et al., ASH 2016; *Venclexta in collaboration with AbbVie; AML=acute myeloid b leukemia; LDAC=low dose cytarabine; o

r 0 .4 ORR=overall response rate; CR=complete response; CRi=complete remission with incompleteP marrow recovery; PR=partial response; 49 PD=progressive disease; BM=bone marrow 0 .3 0 .2 0 .1 I= c e n s o r e d e v e n t 0 .0 0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 M o n th s sin c e in itia tio n o f tre a tm e n t Introduction: Venclexta

Venclexta in CLL

Venclexta in AML

Venclexta in NHL (CAVALLI, CONTRALTO)

Venclexta in MM

Venclexta development program

50 Venclexta* in NHL Early CD20+chemo combination data

Response rates by PET- Arm A Arm B Arm C CT by investigator at 6- VEN + R VEN + BR BR month (primary), n (%) (N=53) (N=51) (N=51) ORR 16 (30) 38 (75) 39 (77) CR 7 (13) 32 (63) 31 (61) PR 9 (17) 6 (12) 8 (16) SD 2 (4) 0 0 PD 24 (45) 2 (4) 6 (12) Data not available 11 (21) 11 (22) 6 (12)

Zelenetz AD. et al., ASH 2016 NHL Zinzani PL. et al., ASH 2016 Arm A Arm B Response by Ven+R-CHOP Ven+G-CHOP PET-CT, n (%) (n=24) (n=25) Phase I/II interim results (CAVALLI): Phase II interim results (CONTRALTO):

ORR 21 (88) 21 (66) • ORR is promising in NHL population • Longer follow-up is required to establish the CR 19 (79) 18 (56) role of Ven + BR in R/R FL PR 2 (8) 3 (9) • High CR rate (7/8; 87.5%) observed in the PD 2 (8) 0 DLBCL population with co-expression of • Higher BCL-2 expression may be associated Missing 1 (4) 4 (13) BCL-2 and Myc, who have a poor prognosis. with higher CR rates with Ven + BR • Ph2 completed enrollment of 210 patients

*Venclexta in collaboration with AbbVie; NHL=non-hodgkin`s lymphoma; R/R FL=relapsed/refractory follicular lymphoma; ; R=Rituxan; B=bendamustine; ORR=overall response rate; PET-CT=positron emission tomography-computed tomography; 51 CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; PFS=progression free survival Introduction: Venclexta

Venclexta in CLL

Venclexta in AML

Venclexta in NHL

Venclexta in MM

Venclexta development program

52 Venclexta

Venclexta* in R/R MM All non- patients t(11;14) t(11;14) Combination efficacy data (n=66) (n=30) (n=36) ORR, n (%) 14 (21) 12 (40) 2 (6) sCR 2 (3) 1 (4) 1 (3) CR 3 (5) 3 (10) 0 VGPR 5 (8) 4 (13) 1 (3) Started Ph3 PR 4 (6) 4 (13) 0 Should we show the data?

Venclexta + dexamethasone + bortezomib

non-refractory refractory to All patients to bortezomib bortezomib (n=66) (n=39) (n=26)

Moreau P. et al., ASH 2016 ORR, n (%) 44 (67) 35 (90) 8 (31) sCR 3 (5) 3 (8) 0 Phase I combination results: CR 10 (15) 8 (20) 1 (4)

• Combination was well tolerated VGPR 15 (23) 14 (36) 1 (4) PR 16 (24) 10 (26) 6 (23) • Patients non-refractory to bortezomib had an ORR of 90% and reponses were more durable (median TTP, 11.3 vs 1.8 months) • Results support on-going Ph3 trial in R/R MM

*Venclexta in collaboration with AbbVie; R/R MM=relapsed/refractory multiple myeloma; ORR=objective response rate; sCR=surgical complete response; CR=complete response; VGPR=very good partial response; PR=partial response; TTP=time to progression 53

Introduction: Venclexta

Venclexta in CLL

Venclexta in AML

Venclexta in NHL

Venclexta in MM

Venclexta development program

54 Development program in NHL Venclexta trials in NHL…

Compound Combination Study name Indication PPh1 1 PPh2 2 PPh3 3 Gazyva +bendamustine GADOLIN FL (iNHL) (Rituxan refractory)  Gazyva +CHOP GOYA 1L DLBCL (aNHL)  Gazyva +chemo GALLIUM 1L FL ( iNHL)  Venclexta* +Rituxan/+Rituxan+bendamustine CONTRALTO R/R FL (iNHL) ASH Venclexta +Rituxan+CHOP CAVALLI 1L DLBCL (aNHL) ASH Venclexta +Rituxan+bendamustine R/R NHL Venclexta R/R CLL and R/R NHL Venclexta +Gazyva/Rituxan+polatuzumab R/R DLBCL (aNHL) and R/R FL (iNHL) polatuzumab +Rituxan/Gazyva ROMULUS R/R DLBCL (aNHL) and R/R FL (iNHL) NHL polatuzumab +Gazyva/Rituxan+bendamustin R/R DLBCL (aNHL) and R/R FL (iNHL) polatuzumab +Gazyva+CHP/Rituxan+CHP 1L DLBCL (aNHL) polatuzumab +Gazyva/Rituxan+lenalidomide R/R DLBCL (aNHL) and R/R FL (iNHL) +Gazyva or Tecentriq R/R DLBCL (aNHL) and R/R FL (iNHL) +tazemetostat1** Tecentriq +Gazyva+lenalidomide R/R FL (iNHL) Tecentriq +Gazyva/Rituxan+benda or CHOP 1L FL (iNHL) and 1L DLBCL (aNHL) Tecentriq +Gazyva/Rituxan+polatuzumab R/R DLBCL (aNHL) and R/R FL (iNHL) idasanutlin +Gazyva/Rituxan R/R DLBCL (aNHL) and R/R FL (iNHL) undisclosed ADC R/R NHL

iNHL=indolent non-hodgkin`s lymphoma; aNHL=agressive NHL; DLBCL=diffuse large B cell lymphoma; FL=follicular lymphoma; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; * Venclexta in collaboration with AbbVie; Gazyva in 55 collaboration with Biogen; polatuzumab vedotin in collaboration with Seattle Genetics; **External collaboration; ADC=antibody drug conjugate Development program in CLL, MM, AML, MDS …CLL, MM and AML

Compound Combination Study name Indication Ph1P 1 Ph2P 2 Ph3P 3 Gazyva +chemo CLL11 CLL  Gazyva +FC/bendamustin/Clb GREEN CLL and R/R CLL Venclexta +Rituxan R/R CLL and SLL Venclexta +Gazyva CLL14 CLL ASH CLL Venclexta +Rituxan MURANO R/R CLL Venclexta R/R CLL 17p  Venclexta R/R CLL after ibru/idel ASH Venclexta +Rituxan+bendamustine R/R CLL and untreated CLL ASH Venclexta +Gazyva R/R CLL and untreated CLL Venclexta R/R MM ASH Venclexta +bortezomib+dexamethasone R/R MM ASH MM monotherapy or +daratumumab** or Tecentriq R/R MM +lenalidomide or +lenalidomide+daratumumab Venclexta AML Venclexta +decitabine/+azacitidine AML Venclexta +low dose cytarabine (LDAC) 1L AML ASH AML +Cotellic Venclexta R/R AML unfit for chemo +idasanutlin LSD1 inhibitor AML idasanutlin +cytarabine R/R AML MDS Tecentriq +azacitidine MDS aCD20/CD3 TCB1 Hematologic tumors

CLL=chronic lymphoid leukemia; R/R CLL=relapsed/refractory CLL; MM=multiple myeloma; AML=acute myeloid leukemia; MDS=myelodysplastic syndrome; FC=fludarabine, cyclophosphamide; *Venclexta in collaboration with AbbVie; Gazyva in collaboration 56 with Biogen; Cotellic in collaboration with Exelixis; **External collaboration Polatuzumab vedotin – A potent ADC in NHL

Michael Wenger, M.D. Senior Group Medical Director Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

58 MoA: Polatuzumab vedotin (anti-CD79b ADC) Potential to become part of a future backbone

2 Anti-CD79b targets to B-cell malignancies 1 3 MMAE Microtubule disrupter

Variable chain linker 4 cleavable by lysosomal proteases 6 5

Product profile

• ADC designed for targeting microtubule inhibitor MMAE to cells expressing CD79b

• Linker is stable in the bloodstream but releases the drug payload inside the target cell

MOA=mechanism of action; ADC=antibody drug conjugate; MMAE=monomethyl auristatin E 59 Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

60 Polatuzumab + Rituxan-CHP in 1L DLBCL Early efficacy and safety data

Pola + Rituxan-CHP Study design End of treatment responses by PET-CT Pola <1.8 mg/kg Pola 1.8 mg/kg (n=5) (n=33)

CR, n (%) 4 (80) 23 (70) PR, n (%) 1 (20) 5 (15) PD, n (%) 0 3 (9) Not evaluable, n (%) 0 2 (6)

Duration of response

Phase Ib/II results

Polatuzumab + G-CHP** • Phase 2 dose of 1.8 mg/kg established Pola 1.4 mg/kg Pola 1.8 mg/kg • Safety profile is inline with R-CHOP CR 3 (75) CR 3 (75) DLBCL (N=4) • CR of 70% and PR of 15% achieved SD 1 (25) SD 1 (25) • Efficacy promising as patients treated in the MCL (N=1) CR 1 (100) CR 1 (100) dose-expansion were strongly weighted in Relapsed FL CR 1 (100) CR 1 (100) the high-risk category by the IPI (N=1)

Tilly H. et al., ASH 2016; DLBCL=diffuse large B cell lymphoma; CHP=cyclophosphamide, doxorubicin and prednisone; CR=complete Pola 1.8mg/kg Ph II expansion responses; PR=partial responses; PD=progressive disease; IPI=International Prognostic Index 61 n=45

Pola 1.4mg/kg n=3

Pola 1 mg/kg n=2 Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

62 FL DLBCL (n=35) (n=43) Polatuzumab + Gazyva in R/R FL/DLBCL ORR, n (%) 24 (69) 17 (40) CR, n (%) 11 (31) 9 (21) Promising early efficacy PR, n (%) 13 (37) 8 (19) SD, n (%) 4 (11) 0 FL: Overall response by PET-CT PD, n (%) 1 (3) 18 (42)

ROMULUS phase II results: DLBCL: Overall response by PET-CT

• Acceptable safety profile • Promising clinical activity in heavily pretreated R/R FL or DLBCL patients • ORR observed in 69% of FL and 40% of DLBCL patients

Phillips T. et al., ASH 2016; R/R=relapsed/refractory; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; ORR=objective response rate; CR=complete responses; PR=partial responses; SD=stable disease; PD=progressive disease; PFS=progression free 63 survival; PET-CT=positron emission tomography–computed tomography; Data cut-off: July 26, 2016

Polatuzumab + BR/BG in R/R FL/DLBCL R/R FL R/R DLBCL Pola + BR Pola + BG Pola + BR Pola + BG Promising efficacy with bendamustine (n=6) (n=6) (n=6) (n=26) ORR, n (%) 6 (100) 6 (100) 3 (50) 16 (61) CR 5 (83) 5 (83) 2 (33) 10 (38) R/R FL: Overall response by PET-CT PR 1 (17) 1 (17) 1 (17) 6 (23) SD, n (%) 0 0 0 2 (8) PD, n (%) 0 0 2 (33) 4 (15)

Phase Ib/II results: R/R DLBCL: Overall response by PET-CT

• Acceptable safety profile • Clinical activity in heavily pretreated R/R FL or DLBCL patients • Enrollment for Ph2 expansion and randomization part (overall 200 patients) has been completed

Herrera A. et al., ASH 2016; R/R=relapsed/refractory; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; BR=bendamustine+Rituxan; BG=bendamustine+Gazyva; ORR=objective response rate; CR=complete responses; PR=partial 64 responses; SD=stable disease; PD=progressive disease; PET-CT=positron emission tomography–computed tomography; Data cut-off: July 26, 2016

Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

65 Development program in NHL Polatuzumab vedotin trials in FL and DLBCL

Compound Combination Study name Indication PPh1 1 PPh2 2 PPh3 3 Gazyva +bendamustine GADOLIN FL (iNHL) (Rituxan refractory)  Gazyva +CHOP GOYA 1L DLBCL (aNHL)  Gazyva +chemo GALLIUM 1L FL ( iNHL)  Venclexta* +Rituxan/+Rituxan+bendamustine CONTRALTO R/R FL (iNHL) Venclexta +Rituxan+CHOP CAVALLI 1L DLBCL (aNHL) Venclexta +Rituxan+bendamustine R/R NHL Venclexta R/R CLL and R/R NHL Venclexta +Gazyva/Rituxan+polatuzumab R/R DLBCL (aNHL) and R/R FL (iNHL) polatuzumab +Rituxan/Gazyva ROMULUS R/R DLBCL (aNHL) and R/R FL (iNHL) ASH NHL polatuzumab +Gazyva/Rituxan+bendamustin R/R DLBCL (aNHL) and R/R FL (iNHL) ASH polatuzumab +Gazyva+CHP/Rituxan+CHP 1L DLBCL (aNHL) ASH polatuzumab +Gazyva/Rituxan+lenalidomide R/R DLBCL (aNHL) and R/R FL (iNHL) +Gazyva or Tecentriq R/R DLBCL (aNHL) and R/R FL (iNHL) +tazemetostat1** Tecentriq +Gazyva+lenalidomide R/R FL (iNHL) Tecentriq +Gazyva/Rituxan+benda or CHOP 1L FL (iNHL) and 1L DLBCL (aNHL) Tecentriq +Gazyva/Rituxan+polatuzumab R/R DLBCL (aNHL) and R/R FL (iNHL) idasanutlin +Gazyva/Rituxan R/R DLBCL (aNHL) and R/R FL (iNHL) undisclosed ADC R/R NHL

iNHL=indolent non-hodgkin`s lymphoma; aNHL=agressive NHL; DLBCL=diffuse large B cell lymphoma; FL=follicular lymphoma; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; * Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; polatuzumab vedotin in collaboration with Seattle Genetics; **External collaboration; ADC=antibody drug conjugate 66 Doing now what patients need next